Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain’s 2023–2024 RSV Immunisation Campaign

Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain’s 2023–2024 RSV Immunisation Campaign

<b>Background:</b> Respiratory syncytial virus (RSV) poses a significant health burden in children, being the major cause of lower respiratory tract infection (LRTI), including bronchiolitis. During the 2023–2024 RSV season, Spain introduced nirsevimab, a monoclonal antibody for universa...

Full description

Saved in:
Bibliographic Details
Main Authors: Pablo Estrella-Porter, Elisa Correcher-Martínez, Alejandro Orrico-Sánchez, Juan José Carreras
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Vaccines
Subjects:
respiratory syncytial virus
nirsevimab
monoclonal antibodies
safety profile
infants
Online Access:https://www.mdpi.com/2076-393X/13/6/623
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-393X/13/6/623

Similar Items